Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein

THE MDM2 proto-oncogene is found amplified in a variety of tumours1. The oncogenic capacity of the MDM2 protein is attributed to its ability to bind the p53 tumour-suppressor protein and mask its transcriptional activation potential2,3. Here we show that MDM2 makes a functional contact with two cooperating transcription factors, E2F1 and DPI (refs 4, 5), which are involved in S-phase progression6. MDM2 contacts the activation domain of E2F1 using residues conserved in the activation domain of p53. However, in contrast to its repression of p53 activity, MDM2 stimulates the activation capacity of E2F1/DP1. These results indicate that MDM2 not only releases a proliferative block by silencing the tumour suppressor p53, it also positively augments proliferation by stimulating the S-phase inducing transcription factors E2F1/DPI.

[1]  P. Meltzer,et al.  Amplification of a gene encoding a p53-associated protein in human sarcomas , 1992, Nature.

[2]  L. Johnston,et al.  Functional synergy between DP‐1 and E2F‐1 in the cell cycle‐regulating transcription factor DRTF1/E2F. , 1993, The EMBO journal.

[3]  G. Zambetti,et al.  Wild-type p53 binds to the TATA-binding protein and represses transcription. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[4]  Michael R. Green,et al.  Transcription activation by the adenovirus E1a protein , 1989, Nature.

[5]  K. Kinzler,et al.  Oncogenic forms of p53 inhibit p53-regulated gene expression , 1992 .

[6]  B. Vogelstein,et al.  Suppression of human colorectal carcinoma cell growth by wild-type p53. , 1990, Science.

[7]  R Girling,et al.  DP‐1: a cell cycle‐regulated and phosphorylated component of transcription factor DRTF1/E2F which is functionally important for recognition by pRb and the adenovirus E4 orf 6/7 protein. , 1994, The EMBO journal.

[8]  M. Oren,et al.  Regulation of mdm2 expression by p53: alternative promoters produce transcripts with nonidentical translation potential. , 1994, Genes & development.

[9]  W. Kaelin,et al.  E2F-1-mediated transactivation is inhibited by complex formation with the retinoblastoma susceptibility gene product. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[10]  S. Deb,et al.  The tumor suppressor p53 and the oncoprotein simian virus 40 T antigen bind to overlapping domains on the MDM2 protein , 1993, Molecular and cellular biology.

[11]  D. Lane,et al.  Immunochemical analysis of the interaction of p53 with MDM2;--fine mapping of the MDM2 binding site on p53 using synthetic peptides. , 1994, Oncogene.

[12]  J. Nevins,et al.  Expression of transcription factor E2F1 induces quiescent cells to enter S phase , 1993, Nature.

[13]  Marc Vidal,et al.  A cDNA encoding a pRB-binding protein with properties of the transcription factor E2F , 1992, Cell.

[14]  A. Levine,et al.  The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation , 1992, Cell.

[15]  K. Helin,et al.  Heterodimerization of the transcription factors E2F-1 and DP-1 leads to cooperative trans-activation. , 1993, Genes & development.

[16]  C. Miller,et al.  The p53 activation domain binds the TATA box-binding polypeptide in Holo-TFIID, and a neighboring p53 domain inhibits transcription , 1993, Molecular and cellular biology.

[17]  Peggy J. Farnham,et al.  Expression cloning of a cDNA encoding a retinoblastoma-binding protein with E2F-like properties , 1992, Cell.

[18]  Bert Vogelstein,et al.  Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53 , 1993, Nature.

[19]  J. Landers,et al.  Physical and functional interaction between wild-type p53 and mdm2 proteins , 1994, Molecular and cellular biology.

[20]  N. L. La Thangue,et al.  Adenovirus E1a prevents the retinoblastoma gene product from repressing the activity of a cellular transcription factor. , 1992, The EMBO journal.

[21]  T. Kouzarides,et al.  The retinoblastoma protein binds E2F residues required for activation in vivo and TBP binding in vitro. , 1993, Nucleic acids research.